10% Of AIA Petitions Have Been For Pharma, Biologic Patents

By Dani Kass (August 12, 2021, 7:02 PM EDT) -- Since September 2012, only about 10% of America Invents Act petitions have been targeted at the pharmaceutical and biologic industries, according to new data from the U.S. Patent and Trademark Office.

Of the 13,200 AIA petitions filed between Sept. 16, 2012, and June 30, 2021, some 4% were for Orange Book patents, 2% were for biologic patents and another 4% were for additional biologic and pharmaceutical patents, according to the USPTO. That compares to about 60% of AIA petitions targeting electrical and computer patents and 24% seeking review of mechanical and business method patents.

@media screen and (min-width: 500px) { .image-margin {margin-left:20px...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!